Physician profile
Muhammad Ansari
NPI 1225103765
$11,360.14
in general payments reported to CMS, 2019-2025
40 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $634 · 2021: $1,495 · 2022: $1,175 · 2023: $962 · 2024: $2,251 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Travel and Lodging: $2,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.67 |
| Travel and Lodging | $2,232.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,249.50 | 2019-2025 | Lifevest |
| Medtronic, INC. | $1,907.95 | 2021-2025 | Symplicity G3, Linq II, Cougar Xt |
| Angiodynamics, INC. | $1,420.59 | 2024 | Auryon Laser System 100-120 Vac |
| Bard Peripheral Vascular, INC. | $786.05 | 2025 | Crosser Iq |
| Abbott Laboratories | $758.39 | 2019-2024 | Esprit, Acculink, Jeti Peripheral Catheter |
| Janssen Pharmaceuticals, INC | $735.15 | 2019-2023 | Xarelto |
| Amgen INC. | $590.57 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Novartis Pharmaceuticals Corporation | $409.41 | 2019-2025 | |
| Pfizer INC. | $276.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.71 | 2019-2024 | Eliquis |
| Edwards Lifesciences Corporation | $210.76 | 2019-2024 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $188.81 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $187.33 | 2023-2025 | Impella |
| Boston Scientific Corporation | $145.11 | 2019-2024 | Rotablator Rotational Atherectomy System Console Kit |
| Astrazeneca Pharmaceuticals LP | $143.35 | 2019-2024 | Farxiga |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.